Core Insights - Alumis Inc (NASDAQ:ALMS) shares surged by 107.9% to $17.28 after the company announced that its plaque psoriasis drug, envudeucitinib, successfully met all primary and secondary endpoints in both phase three trials [1] Group 1: Stock Performance - ALMS has reached record highs today, aiming to end a seven-day losing streak and potentially achieving its best day on record, with a year-over-year increase of approximately 100% [2] - The stock's options market is experiencing significant activity, with 3,492 calls and 5,948 puts traded, which is 39 times the average daily options volume [3] Group 2: Market Dynamics - The stock has been placed on the short sell restricted (SSR) list due to its volatility, with short interest accounting for 6.2% of the available float, equating to four days of potential buying power [4]
Alumis Stock Hits Record High on Psoriasis Drug Trial Results